Related Experiment Video
Updated: Jul 28, 2026

Using Adeno-associated Virus as a Tool to Study Retinal Barriers in Disease
Published on: April 19, 2015
Cytomegalovirus Retinitis in a Patient Taking Upadacitinib: A Case Report
Hiromasa Hirai1, Yasuhiro Akai2, Nahoko Ogata1
1Ophthalmology, Nara Medical University, Kashihara, JPN.
Abstract:
Upadacitinib is a relatively new drug used to treat autoimmune diseases. However, patients treated with upadacitinib may develop infections. We report a case of cytomegalovirus (CMV) retinitis that developed during upadacitinib administration. A 79-year-old woman presented with progressively decreasing vision in both eyes. Her decimal best-corrected visual acuity (BCVA) was 0.2 in the right and 0.01 in the left eye. The patient was taking upadacitinib for one year. Fundus examination revealed vitreous opacities and extensive white retinal lesions with hemorrhage in both eyes. CMV was detected in the anterior aqueous humor, vitreous humor, and blood samples. We diagnosed her with panuveitis and CMV retinitis, performed a vitrectomy in both eyes, and administered intravenous ganciclovir and steroids. After treatment, her BCVA improved to 0.6 in the right and 0.1 in the left eye. Ophthalmologists and physicians should be aware of CMV infections in patients being treated with upadacitinib.
Related Concept Videos
Glaucoma: Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Cytomegalovirus Disease
Diabetic Retinopathy
Diabetic Nephropathy

